@article{enomoto_elliot_petritz_crespo_yeatts_sheela_fricke_singleton_thomson_baynes_2024, title={Residue, distribution and depletion of fluralaner in egg following a single intravenous and transdermal administration in healthy shaver hens: fluralaner residue in egg}, volume={103}, ISSN={["1525-3171"]}, url={https://doi.org/10.1016/j.psj.2024.103843}, DOI={10.1016/j.psj.2024.103843}, abstractNote={The demand for the use of fluralaner in an extra label manner is increasing due to lack of efficacious treatment to combat mites and bed bugs in the poultry industry in the United States. Fluralaner residue data in eggs is lacking and residues might cause risks to human health. The present study aimed to determine the depletion profiles of fluralaner in eggs and estimate the drug withdrawal interval in whole eggs by adopting the US Food and Drug administration tolerance limit method with single intravenous (0.5 mg/kg) or transdermal administration (average 58.7 mg/kg) in healthy shaver hens. Hens were treated intravenously or trans-dermally with fluralaner. The eggs were collected daily for 28 days for intravenous treated and for 40 days from the transdermal route group. Fluralaner concentrations in yolk and albumen were determined by mass spectrometry. The greater percentage of fluralaner was observed in yolk when compared to the albumen for both administration routes. Non-compartmental analysis was used to calculate the pharmacokinetic parameters in yolk, albumen and whole egg. The longest apparent half-life confirmed in yolk was 3.7 days for intravenous and 14.3 days for the transdermal route. The withdrawal intervals in whole egg for fluralaner following the intravenous and transdermal administration were 7 days and 81 days, respectively, with maximum residue limits (1.3 µg/g) at 13 days and 171 days, respectively, based on the limit of quantification (0.4 µg/g) from the analytical assay reported by EMA and APVMA.}, number={7}, journal={POULTRY SCIENCE}, author={Enomoto, Hiroko and Elliot, Baxter A. and Petritz, Olivia A. and Crespo, Rocio and Yeatts, James and Sheela, Farha Ferdous and Fricke, Isabel and Singleton, Abby and Thomson, Andrea and Baynes, Ronald E.}, year={2024}, month={Jul} }
 @article{meira_wiloch_nixon_yeatts_sheela_smith_baynes_2022, title={The pharmacokinetics of transdermal flunixin in lactating dairy goats}, volume={105}, ISSN={["1525-3198"]}, url={https://doi.org/10.3168/jds.2021-20460}, DOI={10.3168/jds.2021-20460}, abstractNote={Flunixin is a nonsteroidal anti-inflammatory drug approved for use in cattle to manage pyrexia associated with bovine respiratory disease, mastitis, and endotoxemia. In the United States, no nonsteroidal anti-inflammatory drugs are approved for use in goats, but analgesics are needed for management of painful conditions to improve animal welfare. The objective of this study was to evaluate the pharmacokinetics of transdermal flunixin in dairy goats to determine a milk withdrawal interval (WDI) to avoid violative residue contamination in the food supply. Six adult lactating dairy goats received 3.3 mg/kg of transdermal flunixin before milk, interstitial fluid (ISF), and blood samples were collected at various time points for 360 h. The samples were analyzed using tandem mass spectrometry to detect flunixin as well as the flunixin marker metabolite, 5-hydroxyflunixin followed by a pharmacokinetic WDI calculation using the US Food and Drug Administration tolerance limit method to propose safe residue levels in goat milk. The mean flunixin apparent plasma half-life was 21.63 h. The apparent milk half-life for 5-hydroxyflunixin was 17.52 h. Our findings provide a milk WDI of 60 h using the US Food and Drug Administration tolerance of 0.002 µg/mL (established for bovine milk) and a more conservative WDI of 96 h using a limit of quantification of 0.001 µg/mL following the extralabel use of transdermal flunixin in dairy goats.}, number={1}, journal={JOURNAL OF DAIRY SCIENCE}, publisher={American Dairy Science Association}, author={Meira, Enoch B. de S., Jr Jr and Wiloch, Emily E. and Nixon, Emma and Yeatts, James L. and Sheela, Farha Ferdous and Smith, Geof W. and Baynes, Ronald E.}, year={2022}, month={Jan}, pages={549–559} }